Femasys (NASDAQ:FEMY) Stock Rating Lowered by Wall Street Zen

Femasys (NASDAQ:FEMY) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other research firms have also issued reports on FEMY. Weiss Ratings restated a “sell (e+)” rating on shares of Femasys in a report on Thursday, January 22nd. Lake Street Capital began coverage on Femasys in a research report on Tuesday, March 3rd. They set a “buy” rating and a $1.50 price objective for the company. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $5.50.

Femasys Stock Down 3.2%

Femasys stock opened at $0.48 on Friday. Femasys has a fifty-two week low of $0.31 and a fifty-two week high of $1.39. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.61 and a current ratio of 1.16. The firm has a 50 day moving average price of $0.55 and a 200 day moving average price of $0.63. The company has a market capitalization of $28.21 million, a PE ratio of -0.67 and a beta of -2.53.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Geode Capital Management LLC boosted its holdings in shares of Femasys by 50.8% in the fourth quarter. Geode Capital Management LLC now owns 389,280 shares of the company’s stock valued at $224,000 after acquiring an additional 131,052 shares in the last quarter. Banco BTG Pactual S.A. purchased a new position in Femasys during the fourth quarter worth about $88,000. Jane Street Group LLC acquired a new stake in Femasys in the fourth quarter valued at about $62,000. State Street Corp lifted its position in Femasys by 43.5% in the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after purchasing an additional 24,500 shares during the period. Finally, Cetera Investment Advisers purchased a new stake in Femasys in the 4th quarter valued at approximately $36,000. Institutional investors and hedge funds own 65.27% of the company’s stock.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.